NO20042634L - 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser - Google Patents
3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaserInfo
- Publication number
- NO20042634L NO20042634L NO20042634A NO20042634A NO20042634L NO 20042634 L NO20042634 L NO 20042634L NO 20042634 A NO20042634 A NO 20042634A NO 20042634 A NO20042634 A NO 20042634A NO 20042634 L NO20042634 L NO 20042634L
- Authority
- NO
- Norway
- Prior art keywords
- cyanoquinolines
- egf
- inhibitors
- her2 kinases
- her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33356801P | 2001-11-27 | 2001-11-27 | |
PCT/US2002/037918 WO2003050090A1 (en) | 2001-11-27 | 2002-11-26 | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20042634L true NO20042634L (no) | 2004-06-23 |
Family
ID=23303345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042634A NO20042634L (no) | 2001-11-27 | 2004-06-23 | 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser |
Country Status (24)
Country | Link |
---|---|
US (1) | US6821988B2 (uk) |
EP (1) | EP1448531B1 (uk) |
JP (1) | JP2005514384A (uk) |
KR (1) | KR20050044599A (uk) |
CN (1) | CN1659145A (uk) |
AR (1) | AR037438A1 (uk) |
AT (1) | ATE370123T1 (uk) |
AU (1) | AU2002359489B2 (uk) |
BR (1) | BR0214485A (uk) |
CA (1) | CA2467573A1 (uk) |
CO (1) | CO5580828A2 (uk) |
DE (1) | DE60221886D1 (uk) |
EC (1) | ECSP045122A (uk) |
HU (1) | HUP0402228A2 (uk) |
IL (1) | IL161921A0 (uk) |
MX (1) | MXPA04004969A (uk) |
NO (1) | NO20042634L (uk) |
NZ (1) | NZ533118A (uk) |
PL (1) | PL370137A1 (uk) |
RU (1) | RU2309150C2 (uk) |
TW (1) | TW200300348A (uk) |
UA (1) | UA77469C2 (uk) |
WO (1) | WO2003050090A1 (uk) |
ZA (1) | ZA200405025B (uk) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
WO2005018677A2 (en) * | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
EP1670473A1 (en) * | 2003-09-15 | 2006-06-21 | Wyeth a Corporation of the State of Delaware | Substituted quinolines as protein tyrosine kinase enzyme inhibitors |
US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
US7365203B2 (en) * | 2003-09-15 | 2008-04-29 | Wyeth | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile |
JP4638436B2 (ja) | 2003-09-26 | 2011-02-23 | エグゼリクシス, インコーポレイテッド | c−Metモジュレーターおよびその使用 |
US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
CA2575466A1 (en) | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Thiazole based inhibitors of atp-utilizing enzymes |
JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
TW200616612A (en) * | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
US7624279B2 (en) * | 2005-06-29 | 2009-11-24 | Lenovo Singapore Pte. Ltd. | System and method for secure O.S. boot from password-protected HDD |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
JP5190361B2 (ja) | 2006-05-18 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 甲状腺癌に対する抗腫瘍剤 |
AU2007258237A1 (en) * | 2006-06-13 | 2007-12-21 | Wyeth | Substituted 3-cyanopyridines as protein kinase inhibitors |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
ITMI20082336A1 (it) * | 2008-12-29 | 2010-06-30 | Univ Parma | Composti inibitori irreversibili di egfr con attivita' antiproliferativa |
TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CA2780332C (en) | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
RU2600928C2 (ru) * | 2010-06-09 | 2016-10-27 | Тяньцзинь Химэй Байо-Тек Ко., Лтд | Цианохинолиновые производные |
CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
ES2545353T3 (es) | 2010-08-26 | 2015-09-10 | Symphony Evolution, Inc. | Uso de un modulador de quinasa de tipo receptor para el tratamiento de la enfermedad poliquística del riñón |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CN102675287A (zh) * | 2011-03-11 | 2012-09-19 | 江苏恒瑞医药股份有限公司 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
WO2014098176A1 (ja) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
CN103304494B (zh) * | 2013-06-20 | 2015-05-27 | 河北大学 | 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途 |
MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
JP6757959B2 (ja) | 2015-06-16 | 2020-09-23 | 株式会社 PRISM BioLab | 抗がん剤 |
US10774068B2 (en) * | 2015-06-25 | 2020-09-15 | The Scripps Research Institute | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 |
WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
CN115057861A (zh) * | 2016-03-01 | 2022-09-16 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
MD3658552T2 (ro) | 2017-07-28 | 2024-02-29 | Yuhan Corp | Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil |
CN110452232A (zh) * | 2019-09-17 | 2019-11-15 | 北京振东光明药物研究院有限公司 | 阿法替尼杂质化合物及其制备方法与应用 |
CN111995618B (zh) * | 2020-09-02 | 2021-06-11 | 重庆医科大学 | 一种来那替尼杂质g的制备方法 |
CN111943933B (zh) * | 2020-09-02 | 2021-05-28 | 重庆医科大学 | 一种来那替尼杂质d的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK285141B6 (sk) * | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
ES2457396T3 (es) * | 1998-09-29 | 2014-04-25 | Wyeth Holdings Llc | 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas |
JP4548642B2 (ja) * | 1998-09-29 | 2010-09-22 | アメリカン・サイアナミド・カンパニー | プロテインチロシンキナーゼインヒビターとしての置換3−シアノキノリン |
GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
DK1242382T3 (da) * | 1999-12-29 | 2007-05-07 | Wyeth Corp | Tricycliske proteinkinaseinhibitorer |
AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
-
2002
- 2002-11-26 BR BR0214485-9A patent/BR0214485A/pt not_active IP Right Cessation
- 2002-11-26 JP JP2003551115A patent/JP2005514384A/ja not_active Ceased
- 2002-11-26 IL IL16192102A patent/IL161921A0/xx unknown
- 2002-11-26 AU AU2002359489A patent/AU2002359489B2/en not_active Ceased
- 2002-11-26 AR ARP020104543A patent/AR037438A1/es not_active Application Discontinuation
- 2002-11-26 HU HU0402228A patent/HUP0402228A2/hu unknown
- 2002-11-26 CA CA002467573A patent/CA2467573A1/en not_active Abandoned
- 2002-11-26 WO PCT/US2002/037918 patent/WO2003050090A1/en active IP Right Grant
- 2002-11-26 NZ NZ533118A patent/NZ533118A/en unknown
- 2002-11-26 UA UA20040605019A patent/UA77469C2/uk unknown
- 2002-11-26 RU RU2004119414/04A patent/RU2309150C2/ru not_active IP Right Cessation
- 2002-11-26 MX MXPA04004969A patent/MXPA04004969A/es active IP Right Grant
- 2002-11-26 TW TW091134370A patent/TW200300348A/zh unknown
- 2002-11-26 EP EP02794031A patent/EP1448531B1/en not_active Expired - Lifetime
- 2002-11-26 US US10/305,438 patent/US6821988B2/en not_active Expired - Fee Related
- 2002-11-26 PL PL02370137A patent/PL370137A1/xx not_active Application Discontinuation
- 2002-11-26 DE DE60221886T patent/DE60221886D1/de not_active Expired - Lifetime
- 2002-11-26 KR KR1020047007951A patent/KR20050044599A/ko not_active Application Discontinuation
- 2002-11-26 CN CN028275381A patent/CN1659145A/zh active Pending
- 2002-11-26 AT AT02794031T patent/ATE370123T1/de not_active IP Right Cessation
-
2004
- 2004-05-25 CO CO04048181A patent/CO5580828A2/es not_active Application Discontinuation
- 2004-05-26 EC EC2004005122A patent/ECSP045122A/es unknown
- 2004-06-23 NO NO20042634A patent/NO20042634L/no not_active Application Discontinuation
- 2004-06-24 ZA ZA200405025A patent/ZA200405025B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL370137A1 (en) | 2005-05-16 |
DE60221886D1 (de) | 2007-09-27 |
UA77469C2 (en) | 2006-12-15 |
CA2467573A1 (en) | 2003-06-19 |
MXPA04004969A (es) | 2004-08-11 |
EP1448531B1 (en) | 2007-08-15 |
ECSP045122A (es) | 2004-07-23 |
US20030149056A1 (en) | 2003-08-07 |
RU2004119414A (ru) | 2006-02-27 |
CO5580828A2 (es) | 2005-11-30 |
BR0214485A (pt) | 2004-09-14 |
EP1448531A1 (en) | 2004-08-25 |
JP2005514384A (ja) | 2005-05-19 |
ATE370123T1 (de) | 2007-09-15 |
ZA200405025B (en) | 2006-12-27 |
KR20050044599A (ko) | 2005-05-12 |
AR037438A1 (es) | 2004-11-10 |
AU2002359489A1 (en) | 2003-06-23 |
HUP0402228A2 (hu) | 2005-02-28 |
CN1659145A (zh) | 2005-08-24 |
IL161921A0 (en) | 2005-11-20 |
AU2002359489B2 (en) | 2008-10-30 |
WO2003050090A1 (en) | 2003-06-19 |
RU2309150C2 (ru) | 2007-10-27 |
US6821988B2 (en) | 2004-11-23 |
NZ533118A (en) | 2006-07-28 |
TW200300348A (en) | 2003-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20042634L (no) | 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser | |
NO20050636L (no) | Inhibitorer av tyrosinkinaser | |
NO20052888D0 (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
NO20041582L (no) | Antistoffinhibitorer av GDF-8 og anvendelse derav | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
NO20052595D0 (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
DE60221977D1 (de) | Pro-pharmakon von cox-2-inhibitoren | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
NO20026010L (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
NO20053356L (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
NO20033387D0 (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
DK1370554T3 (da) | 3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer | |
NO20045220L (no) | Heterocykliske inhibitorer for kinaser | |
NO20053242D0 (no) | 4-substituerte benzimidazoler og deres anvendelse som inhibitorer av gastrisk sekresjon. | |
DK1480962T3 (da) | 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer | |
NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
NO20042719L (no) | Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer | |
NO20035328D0 (no) | Nye forbindelser og preparater som katepsinhibitorer | |
EE200300491A (et) | 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena | |
NO20033506D0 (no) | Parasittdrepende preparater og fremgangsmåter for anvendelse | |
MXPA03009257A (es) | Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas. | |
DK1562955T3 (da) | Quinazolinderivater som Src-tyrosinkinaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |